ENDPOINTS

Investors pump $130M into protein degrader startup GlycoEra

Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, has corralled $130 million in Series B funding to get into the clinic. The transatlantic outfit's experimental medicines aim to deplete circulating proteins ...

May 27, 2025 - 12:04
 0
Investors pump $130M into protein degrader startup GlycoEra
Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, has corralled $130 million in Series B funding to get into the clinic. The transatlantic outfit's experimental medicines aim to deplete circulating proteins ...
Read More

Tags:

Previous Article

A New Study Reveals the Makeup of Uranus’ Atmosphere

Next Article

Syndeio debuts with $90M+ to bring together synapse repair drugs

Related Posts

Eisai, Merck stave off generic competition to Lenvima

Eisai, Merck stave off generic competition to Lenvima

May 29, 2025  0

Enliven stops work on solid tumor drug; Pulmatrix to divest assets

Enliven stops work on solid tumor drug; Pulmatrix to di...

May 15, 2025  0

TCG's R&D venture team makes a T cell engager deal with Shanghai biotech

TCG's R&D venture team makes a T cell engager deal with...

May 27, 2025  0